The FDA rounded out the month with the approval of remibrutinib (Rhapside; Novartis), a highly selective Bruton tyrosine kinase inhibitor (BTKi), for patients with chronic spontaneous urticaria (CSU) ...
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced three abstracts from its clinical development programs will be presented at the upcoming ...
PITTSBURGH, Oct. 13, 2025 /PRNewswire/ — PANTHERx ® Rare has been chosen by Chiesi as the exclusive specialty pharmacy to ...
On September 25, the US Food and Drug Administration (FDA) approved Palsonify™ (paltusotine) for the treatment of acromegaly in adults who had an inadequate response to surgery or for whom surgery is ...
Today, a brief rundown of news involving Crinetics and the Food and Drug Administration, as well as updates from Eli Lilly, Biogen and Gossamer Bio that you may have missed. 3 more startups raised ...
I will now turn the call over to Gayathri Diwakar, Head of Investor Relations. Please go ahead. Thank you, operator. Good afternoon, everyone, and thank you for joining us to discuss the FDA approval ...
SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY TM (paltusotine) ...
Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback